Anavex Life Sciences (NASDAQ:AVXL) Stock Price Passes Above Fifty Day Moving Average - What's Next?

Key Points

• AVXL cleared its 50‑day moving average ($4.35) on Wednesday, trading as high as $5.18 and last at $5.00 on roughly 1.5M shares (up ~6.6%), though it remains below the 200‑day MA of $6.24.
• Analyst views are mixed—two Buys, one Hold and one Sell—with an average rating of Hold and an average price target of $22 (notable targets: $20 and $24).
• Anavex is a clinical‑stage biotech focused on blarcamesine for Alzheimer's and Parkinson's dementia; it reported EPS of ($0.06) beating estimates and has a market cap around $463M with ~31.6% institutional ownership.

Anavex Life Sciences Corp. (NASDAQ:AVXL - Get Free Report)'s share price crossed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $4.35 and traded as high as $5.18. Anavex Life Sciences shares last traded at $5.00, with a volume of 1,499,518 shares.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on AVXL. HC Wainwright reiterated a "buy" rating and set a $20.00 price objective on shares of Anavex Life Sciences in a research note on Tuesday, February 10th. Weiss Ratings restated a "sell (d-)" rating on shares of Anavex Life Sciences in a research note on Monday, December 29th. Wall Street Zen raised shares of Anavex Life Sciences from a "sell" rating to a "hold" rating in a research note on Saturday, February 14th. Finally, D. Boral Capital reiterated a "buy" rating and issued a $24.00 price objective on shares of Anavex Life Sciences in a report on Monday, February 9th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Anavex Life Sciences presently has an average rating of "Hold" and an average price target of $22.00.

Anavex Life Sciences Trading Up 6.6%

The company has a market cap of $463.35 million, a P/E ratio of -10.87 and a beta of 1.08. The company's 50-day moving average price is $4.35 and its two-hundred day moving average price is $6.24.

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last issued its quarterly earnings results on Monday, February 9th. The biotechnology company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.04. As a group, analysts anticipate that Anavex Life Sciences Corp. will post -0.69 earnings per share for the current year.

Institutional Investors Weigh In On Anavex Life Sciences

A number of institutional investors have recently made changes to their positions in AVXL. State of Wyoming bought a new position in Anavex Life Sciences during the second quarter worth $26,000. AlphaQuest LLC acquired a new stake in shares of Anavex Life Sciences during the third quarter worth $29,000. Quarry LP bought a new position in shares of Anavex Life Sciences in the 3rd quarter worth about $36,000. SBI Securities Co. Ltd. boosted its holdings in shares of Anavex Life Sciences by 470.0% in the 2nd quarter. SBI Securities Co. Ltd. now owns 4,879 shares of the biotechnology company's stock valued at $45,000 after buying an additional 4,023 shares during the period. Finally, Russell Investments Group Ltd. grew its position in shares of Anavex Life Sciences by 11,540.0% during the 3rd quarter. Russell Investments Group Ltd. now owns 6,984 shares of the biotechnology company's stock valued at $62,000 after buying an additional 6,924 shares during the last quarter. 31.55% of the stock is currently owned by institutional investors.

About Anavex Life Sciences

Anavex Life Sciences Corp is a clinical‐stage biopharmaceutical company focused on the development of novel therapeutics for central nervous system (CNS) disorders. The company applies a proprietary drug discovery platform that targets sigma‐1 and muscarinic receptors to modulate cellular stress pathways and support neuronal function. Headquartered in New York City, Anavex is dedicated to advancing treatments for neurodegenerative and neurodevelopmental diseases with high unmet medical need.

The company's lead product candidate, blarcamesine (ANAVEX2‐73), is a small‐molecule activator of the sigma‐1 receptor currently being evaluated in clinical trials for Alzheimer's disease and Parkinson's disease dementia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.